GBIO vs. NGM, EDIT, MRSN, KMDA, BTMD, JSPR, ACIU, QTTB, CYRX, and KOD
Should you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include NGM Biopharmaceuticals (NGM), Editas Medicine (EDIT), Mersana Therapeutics (MRSN), Kamada (KMDA), biote (BTMD), Jasper Therapeutics (JSPR), AC Immune (ACIU), Q32 Bio (QTTB), Cryoport (CYRX), and Kodiak Sciences (KOD).
Generation Bio vs.
Generation Bio (NASDAQ:GBIO) and NGM Biopharmaceuticals (NASDAQ:NGM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, community ranking, risk and valuation.
Generation Bio has a net margin of -782.86% compared to NGM Biopharmaceuticals' net margin of -3,223.34%. NGM Biopharmaceuticals' return on equity of -77.85% beat Generation Bio's return on equity.
Generation Bio has a beta of 2.82, meaning that its share price is 182% more volatile than the S&P 500. Comparatively, NGM Biopharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.
In the previous week, Generation Bio had 1 more articles in the media than NGM Biopharmaceuticals. MarketBeat recorded 1 mentions for Generation Bio and 0 mentions for NGM Biopharmaceuticals. Generation Bio's average media sentiment score of 0.44 beat NGM Biopharmaceuticals' score of 0.00 indicating that Generation Bio is being referred to more favorably in the media.
Generation Bio has higher revenue and earnings than NGM Biopharmaceuticals. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
Generation Bio received 10 more outperform votes than NGM Biopharmaceuticals when rated by MarketBeat users. Likewise, 70.00% of users gave Generation Bio an outperform vote while only 60.38% of users gave NGM Biopharmaceuticals an outperform vote.
Generation Bio currently has a consensus price target of $7.50, indicating a potential upside of 447.45%. NGM Biopharmaceuticals has a consensus price target of $1.55, indicating a potential upside of 0.65%. Given Generation Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Generation Bio is more favorable than NGM Biopharmaceuticals.
95.2% of Generation Bio shares are held by institutional investors. Comparatively, 75.7% of NGM Biopharmaceuticals shares are held by institutional investors. 21.1% of Generation Bio shares are held by company insiders. Comparatively, 35.9% of NGM Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Generation Bio beats NGM Biopharmaceuticals on 14 of the 18 factors compared between the two stocks.
Get Generation Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Generation Bio Competitors List
Related Companies and Tools
This page (NASDAQ:GBIO) was last updated on 11/23/2024 by MarketBeat.com Staff
